Rel/NF-kB transcription factors control a variety of cellular processes, such as cell growth and apoptosis, that are relevant to oncogenesis, and mutations in genes encoding Rel/NF-kB transcription factors have been found in several human lymphoid cell cancers. In this study, we have used a sensitive cell outgrowth assay to demonstrate that wild-type human c-Rel can malignantly transform primary chicken spleen cells, and that transformation by c-Rel is accelerated by co-expression of Bc1-2. Full-length mouse c-Rel can also transform chicken spleen cells. These results are the ®rst demonstration of a lymphoid cell malignant transforming ability for mammalian Rel/NF-kB transcription factors, and implicate c-Rel as a molecular target for cancer therapeutics. Oncogene (2001) 20, 7098 ± 7103.
The Rel/NF-kB family of transcription factors includes ®ve vertebrate proteins (p50, p52, c-Rel, RelA, RelB) that form homodimers and heterodimers, bind to DNA, and regulate the expression of hundreds of genes involved in a variety of cellular processes, including apoptosis and cell growth (reviewed in Pahl, 1999) . These transcription factors are related through a highly conserved N-terminal DNA binding/dimerization domain called the Rel Homology domain, and cRel, RelA and RelB have distinct C-terminal domains that mediate transcriptional activation of target genes (reviewed in Gilmore, 1999a) . In addition, Rel/NF-kB transcription factors are tightly controlled by subcellular localization: that is, in most normal cell types Rel/ NF-kB dimers are present in the cytoplasm in a latent state bound to an inhibitor (IkB) until an appropriate signal induces the degradation of IkB, which in turn allows the nuclear transport of the Rel/NF-kB dimer.
The Rel/NF-kB signal transduction pathway is also aected in many tumor cells (reviewed in Rayet and GeÂ linas, 1999; Gilmore et al., 2000) . First, ampli®ca-tions, chromosomal translocations, and mutations have been found in the genes encoding Rel/NF-kB transcription factors (and IkB inhibitors) in many human tumors, especially ones of lymphoid origin. Second, many tumor cells have high levels of constitutively nuclear and active NF-kB. Nevertheless, no mammalian Rel/NF-kB transcription factor has been shown to have malignant transforming activity in vitro or in vivo in primary lymphoid cells. Thus, there is some controversy about the role of altered Rel/NF-kB activity in human cancers. Namely, can alterations in this pathway contribute directly to the transformed phenotype or do they only provide an ancillary function, such as resistance to apoptosis (see Barkett and Gilmore, 1999; White and Gilmore, 1997) ?
In contrast to the mammalian Rel proteins, the avian retroviral oncoprotein v-Rel rapidly transforms and immortalizes a variety of avian hematopoietic cells in vivo and in vitro (reviewed in Gilmore, 1999b) . The in vitro transforming and immortalizing activity of v-Rel is dependent on functions in its N-terminal domain (the formation of homodimers and DNA binding) and in its C-terminal domain (transcriptional activation), and on the ability of v-Rel to block apoptosis. Although less ecient than v-Rel, the highly related chicken c-Rel protein can also transform chicken ®broblasts and spleen cells in vitro (HrdlickovaÂ et al., 1994; Kralova et al., 1994; Gilmore et al., 1995) .
In most cases, transformation by v-Rel is measured by its ability to induce colony formation in soft agar after expression in primary chicken spleen or bone marrow cells (Hoelzer et al., 1980; Mosialos et al., 1991) . However, we previously reported the development of a more sensitive liquid culture outgrowth assay to measure the ability of weakly oncogenic v-Rel mutants to transform primary chicken spleen cells . In this assay, primary chicken spleen cells are electroporated with retroviral expression vectors and helper virus DNA, and cultures are passaged in liquid media and monitored daily for the appearance and dominance of vigorously growing, transformed cells. This liquid outgrowth assay is more sensitive than the soft agar colony assay in that it allows for the expansion of the transformed cells over a longer period of time than is permitted in agar. In addition, we have previously shown that the antiapoptotic protein Bc1-2 can enhance the transforming ability of v-Rel mutants that have greatly reduced activity .
In this study, we have used the liquid outgrowth assay to demonstrate that wild-type human c-Rel can transform chicken lymphoid cells in culture, and that this transforming activity is accelerated by Bc1-2. These results are the ®rst demonstration that a mammalian Rel/NF-kB transcription factor has direct transforming activity and provide a cell system for assaying for inhibitors of the oncogenic activity of human c-Rel.
In an eort to determine whether human c-Rel could be oncogenic in vitro, we created retroviral bicistronic expression vectors for human c-rel and neo or chicken bc1-2, and then assessed the abilities of these viruses to transform primary chicken spleen cells in the liquid outgrowth assay (Figure 1a ). In these assays, Bc1-2 alone did not transform chicken spleen cells. However, human c-Rel had transforming activity, as measured by outgrowth of the c-Rel/Neo and c-Rel/Bc1-2 cultures ( Figure 1a ). The appearance of human c-Rel-transformed cultures was accelerated by co-expression of Bc1-2 (Figure 1b) .
The ability of human c-Rel/Neo to transform cells was also reduced as compared to the highly oncogenic v-Rel in that it took approximately 50% longer for cRel/Neo-transformed cultures to emerge (Figure 1b) . Nevertheless, cell cultures transformed by c-Rel/Neo or c-Rel/Bc1-2 grew as vibrant clumps of cells, which were visually indistinguishable from v-Rel-transformed cells (Figure 1c) . Moreover, cells transformed by human cRel have been maintained in continuous passage for several months.
On the other hand, in the more stringent soft agar colony formation assay (Hoelzer et al., 1980; Mosialos et al., 1991) , c-Rel/Neo could not induce colonies, and c-Rel/Bc1-2 induced colonies that were smaller and took longer to emerge than v-Rel-induced colonies (not shown). If, however, c-Rel-transformed cells, which had been established and maintained in liquid culture, Values are the number of transformed plates out of the total number of assay plates. The time to transformation (avg days) was scored when the cultures were overgrown with transformed cells. Results of two independent experiments are shown. IRES, internal ribosome entry sequence. All spleen necrosis virus vectors are on plasmids that were derived from pMH105 (v-Rel/Neo), which was a kind gift of Mark Hannink (University of Missouri) and has been described previously . Plasmid c-Rel/Neo (human c-rel and neo) was constructed by subcloning an XbaI to SpeI fragment containing a full-length human c-rel cDNA into pMH105 that had been digested with XbaI (which removes v-rel). The vector for the expression of chicken bc1-2 alone was created by digesting plasmid v-R273H/Bc1-2 with XbaI and religating to remove the 5' mutant v-rel gene. Plasmid c-Rel/Bc1-2 was then constructed by subcloning the human c-rel XbaI-SpeI fragment at the XbaI site of the Bc1-2 vector. Liquid culture outgrowth transformation assays were performed essentially as described previously . Brie¯y, fresh spleen cells from 19 day old chickens (SPAFAS) were electroporated with 20 mg of rel expression plasmid and 10 mg of Rev-A helper virus plasmid DNA. Every 5 days thereafter, cells were pelleted and the media [Dulbecco's modi®ed Eagle's medium (DMEM) (GIBCO) containing 20% fetal bovine serum (FBS)] was replaced with fresh media. Cultures were scored as transformed when they were overgrown by transformed cells were placed in soft agar, they could form colonies (Figure 1d ). This suggests that human c-Rel-transformed spleen cells acquire an increased ability to form colonies in soft agar after passage in liquid culture.
To con®rm that the c-Rel/Bc1-2-and c-Rel/Neotransformed cell cultures were expressing the appropriate proteins, Western blotting was performed on independently-derived c-Rel/Bc1-2-transformed colonies [isolated from soft agar (not shown)] and on mixed populations of c-Rel/Neo-and c-Rel/Bc1-2-transformed cells isolated from liquid outgrowth assays. The c-Rel/ Bc1-2-transformed cells synthesized a human c-Rel protein that co-migrated with in vitro-translated human c-Rel (Figure 2a) . Moreover, cells transformed by c-Rel/ Bc1-2 overexpressed chicken Bc1-2 at levels similar to that found in cells transformed by a v-Rel/Bc1-2 virus . Cells transformed by the cRel/Neo virus also overexpressed full-length human cRel (Figure 2b ), but expressed considerably less chicken Bc1-2 than cells transformed by the c-Rel/Bc1-2 virus.
Western blotting of c-Rel/Neo-and c-Rel/Bc1-2-transformed cells with an antiserum that recognizes both chicken and human c-Rel indicates that human c-Rel is expressed only 6 ± 7-fold higher than endogenous chicken c-Rel (Figure 2c) . It is not known whether this rather modest overexpression of human c-Rel is oncogenic in human lymphoid cells. Nevertheless, the level of overexpression of human c-Rel that is oncogenic in chicken spleen cells is similar to the level at which c-rel is ampli®ed in several human lymphoid cell cancers (Lu et al., 1991; Houldsworth et al., 1996; Joos et al., 1996; Barth et al., 1998 Barth et al., , 2001 Rao et al., 1998) .
As ®nal con®rmation that human c-Rel could independently transform chicken spleen cells, we Figure 2 Full-length human c-Rel is expressed in transformed chicken spleen cells. (a) Western blotting with antiserum against human c-Rel, Bc1-2 or v-Rel was performed on extracts from cells transformed by the indicated viruses. For human c-Rel/Bc1-2, four independently derived cell lines (from soft agar colonies) (1 ± 4) and one pooled group of cells (P) were analysed. The ®rst lane in the top panel (c-Rel IVT) shows in vitro-translated human c-Rel, synthesized from a GEM4-based plasmid, that was analysed on the same gel and was detected by autoradiography as described previously (Barkett et al., 2001) . To establish clonal cell lines of cRel/Bc1-2 transformed cells, soft agar colony assays were performed as described previously (Mosialos et al., 1991) , and individual colonies were picked and expanded in liquid medium. Pooled transformed cultures were derived as described for Figure 1c . Western blotting was performed on cell extracts containing approximately equal amounts of protein, essentially as described previously . The following primary antisera (and dilutions) were used: anti-c-Rel (a kind gift of Nancy Rice) (1 : 1500); anti-v-Rel (Gilmore and Temin, 1986) (1 : 1000); and anti-Bc1-2 (Santa Cruz catalog number SC-492) (1 : 5000). Immunoreactive proteins were detected with the SupersSignal Extended Duration chemiluminescent detection system (Pierce). (b) Western blotting of extracts from the indicated transformed cell cultures was performed as in (a). (c) Western blotting with an antiv-Rel antiserum [which crossreacts with human and chicken c-Rel (Gilmore and Temin, 1986; Ballard et al., 1990) ] was performed on extracts from cells transformed by vectors encoding the indicated proteins. The human (Hu) and chicken (Ch) c-Rel proteins are designated by arrows, and the ratios of human to chicken c-Rel are indicated below each lane. NA, not applicable infected chicken spleen cells with a retroviral vector that contained only human c-rel (Figure 3a) . The vector containing only human c-rel gene did transform chicken spleen cells (Figure 3a , lower left), and cells transformed by this virus expressed full-length human c-Rel (Figure 3a, lower right) . Furthermore, a viral vector containing mouse c-rel readily transformed chicken spleen cells (not shown), and these transformed cells synthesized a c-Rel protein that is identical in size to in vitro-translated mouse c-Rel (Figure 3b) .
The mechanism by which mouse and human c-Rel proteins transform chicken spleen cells is likely to be analogous to the mechanism by which v-Rel transforms these cells. Namely, mammalian c-Rel homodimers probably activate the transcription of a set of genes similar to that activated by v-Rel (reviewed in Gilmore, 1999b) . Although sequences in the Rel Homology domain are highly similar between chicken, mouse and human c-Rel, there is much less similarity in their C-terminal transactivation domains (Brownell et al., 1989 ; see also Figure 3c ). Thus, if avian Rel proteins (v-Rel or chicken c-Rel) and mammalian c-Rel proteins (mouse and human) transform chicken spleen cells by activating a similar set of genes, then the speci®city for activation of these genes is likely to reside in their related DNA-binding domains and not in their divergent transactivation domains.
We also determined whether the Bc1-2-related antiapoptotic protein Bc1-x L could accelerate transformation by human c-Rel. Co-expression of human Bc1-x L did not accelerate transformation by c-Rel as compared to the c-Rel/Neo virus (Figure 4a ), even though Western blotting con®rmed that c-Rel/Bc1-x Ltransformed cultures were expressing high levels of Bc1-x L (Figure 4b ). In addition, we created a bicistronic expression vector for human c-Rel and a Bc1-2 mutant (DBH4) that is predicted to be proapoptotic (Figure 4a ). In this Bc1-2 mutant, the BH4 domain has been deleted, which has been shown to convert human Bc1-2 from an anti-apoptotic to a pro-apoptotic protein (Cheng et al., 1997) . Coexpression of the pro-apoptotic Bc1-2 mutant DBH4 completely abolished the ability of human c-Rel to transform. These experiments demonstrate that Bc1-x L cannot substitute for Bc1-2 in accelerating transformation by human c-Rel, and that the anti-apoptotic activity of Bc1-2 is required for c-Rel-induced transformation. (Sif et al., 1993) that had been digested with XbaI and SalI. Chicken spleen cells were then transformed in liquid culture (bottom left panel) as described for Figure 1a and Western blotting was performed with anti-Rel antiserum on extracts from cells transformed by the indicated viruses (bottom right panel) as described for Figure 2a. (b) Western blotting was performed on extracts from chicken spleen cells transformed by a mouse (Mo) c-Rel/Bc1-2 vector (not shown) or by a human c-Rel/ Bc1-2 virus. As a control, in vitro-translated mouse c-Rel (IVT) was also analysed on the same gel. The mouse c-Rel/Bc1-2 vector was created by subcloning an XbaI to HindIII/Klenow-treated fragment containing a mouse c-rel cDNA into the human c-Rel/Bc1-2 plasmid that had been digested with XbaI and XhoI/Klenow treated (to replace human c-rel). (c) Shown is the per cent amino acid identity between chicken and human or between mouse and human c-Rel in the Rel Homology (RH) domain or in sequences Cterminal to the RH domain Taken together, the results reported here provide the ®rst direct evidence that a human Rel/NF-kB family member can be oncogenic. That is, using a sensitive transformation assay, we show that wild-type human cRel by itself oncogenic in primary chicken spleen cells and has an accelerated transforming activity in the presence of a strong anti-apoptotic signal provided by Bc1-2. Therefore, human c-Rel joins a group of proteins whose oncogenic activity is enhanced by Bc1-2 (Heuber and Evan, 1998).
The liquid outgrowth transformation assay is likely to be more sensitive for measuring Rel-induced transformation than the soft agar assay for at least two reasons. First, cells transformed by weakly transforming Rel proteins may sometimes require longer to emerge than can be accommodated by the soft agar assay. For example, it is our observation that cells that do not begin to form colonies in agar within approximately 14 days do not develop as colonies due to the agar becoming dehydrated and more restrictive for growth. Second, the non-transformed cells in liquid culture may secrete factors that promote the outgrowth of transformed cells, a process that would not be expected to occur in soft agar. Similar liquid outgrowth assays have been used to measure lymphoid cell transformation by Epstein-Barr virus or by Abl (Henderson et al., 1977; Kaye et al., 1999; Mainville et al., 2001) . In both cases, the time to transform or the number of plates that show growth has also been used as a measure of transforming ability. The time that it takes for the Rel-transformed cells to emerge in liquid culture is probably a re¯ection of both the inherent transforming potency of a given protein and the initial proliferation rate of the transformed cells. Thus, in certain ways, we think it is likely that the liquid outgrowth assay may better re¯ect the development of Rel-induced leukemias in vivo than the soft agar colony formation assay because in leukemias and in the liquid outgrowth assay the growth of tumor cells occurs amidst an excess of normal cells. Indeed, the presence of uninfected cells is required for Epstein-Barr virus to induce transformed lymphoid cell outgrowth in vitro (Henderson et al., 1977) .
Our results suggest that in some human lymphoid cell cancers c-Rel does provide a malignant proliferation signal, and does not only provide anti-apoptotic eects that contribute to oncogenesis or resistance to chemotherapy (reviewed in Barkett and Gilmore, 1999) . Therefore, as we suggested previously (White and Gilmore, 1997) , c-Rel may provide a direct molecular target for anti-cancer therapy, especially in human lymphoid cancers that have ampli®cations or overexpression of c-rel. This is particularly relevant in that over 100 agents are already known to have antiRel/NF-kB activity (Epinat and Gilmore, 1999) .
It is curious that Bc1-x L cannot substitute for Bc1-2 in accelerating transformation by human c-Rel in our chicken spleen cell assay in that these two proteins are interchangeable in many apoptosis protection assays. However, it may be that Bc1-2 has a speci®c function in promoting oncogenesis, especially in human lymphoid cancers. That is, bc1-2 is frequently rearranged or overexpressed in human lymphoid cancers, whereas the bc1-x L gene is rarely, if ever, altered or overexpressed in such cancers.
The cooperation between c-Rel and Bc1-2 that we have observed in the transformation of chicken lymphoid cells may also occur in human lymphoid cancers. For example, rearrangements of bc1-2 are found in several human lymphoid tumors that also have alterations or ampli®cations of human c-rel (Rao et al., 1998) . Of note, overexpression of bc1-2 occurs in a subset of human diuse large B-cell lymphomas (DLBCLs) that have been classi®ed as activated B celllike DLBCLs (Alizadeh et al., 2000) . Given the role of Rel/NF-kB in promoting bc1-2 expression in maturing B cells (Grossmann et al., 2000) , one might speculate that activated B cell-like DLBCLs also have high levels Figure 4 Bc1-x L and a pro-apoptotic form of Bc1-2 cannot accelerate transformation by human c-Rel. (a) The depicted virus constructs were used in transformation assays as in Figure 1a . In plasmid c-Rel/Bc1-x L , the human bc1-x L cDNA was used to replace the 3' neo gene of c-Rel/Neo (Figure 1a) , which was removed by digestion of pMH105 with NcoI and RsrII. Plasmid c-Rel/mBc1-2 contains a mutant chicken bc1-2 gene (mbc1-2), which is lacking the BH4 domain (DBH4), and was made by digesting the bc1-2 gene with NaeI and SmaI and religating; this results in the in-frame deletion of codons 4-33 of chicken bc1-2. This assay was performed as part of Expt 2 in Figure 1a. (b) Western blotting with anti-human c-Rel or anti-Bc1-x L antisera (Transduction Laboratories, catalog number B22630; 1 : 5000) was performed as in Figure 2 of active Rel/NF-kB. As such, the c-Rel-and c-Rel/ Bc1-2-transformed chicken spleen cells could provide an in vitro means for screening for anti-c-Rel inhibitors that have anti-cancer eects, and such inhibitors may synergize with inhibitors of Bc1-2 (Huang, 2000) .
To our knowledge, the ®ndings reported here are the ®rst demonstration that expression of a single, wildtype version of a human gene is sucient to malignantly transform primary lymphoid cells in vitro. The assay that we have used to demonstrate an oncogenic activity for human c-Rel may be useful for detecting a transforming activity of other human proteins whose expression is associated with human leukemogenesis, but that have not been shown to be transforming in tissue culture (reviewed in Bohlander, 2000) . Along these lines, it is not clear whether the chicken target cells in this assay are particularly sensitive to the transforming activity of human c-Rel or whether only chicken Bc1-2 can cooperate with human c-Rel in this assay. In any event, taken together, the simple ®ndings reported here pave the way for a variety of experiments to further explore or to counter the oncogenic activity of human c-Rel.
